Press Releases
GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies
GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September
GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650
GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update
GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress
GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update
GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference
GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022
GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
